Decibel Therapeutics Inc. (DBTX)
Decibel Therapeutics Statistics
Share Statistics
Decibel Therapeutics has 25.13M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 25.13M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 13.4M |
| Failed to Deliver (FTD) Shares | 14.29K |
| FTD / Avg. Volume | 6.66% |
Short Selling Information
The latest short interest is 110.95K, so 0.44% of the outstanding shares have been sold short.
| Short Interest | 110.95K |
| Short % of Shares Out | 0.44% |
| Short % of Float | 0.65% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.81 and the forward PE ratio is null. Decibel Therapeutics's PEG ratio is -0.14.
| PE Ratio | -0.81 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.63 |
| P/FCF Ratio | -0.89 |
| PEG Ratio | -0.14 |
Enterprise Valuation
Decibel Therapeutics has an Enterprise Value (EV) of 30.61M.
| EV / Sales | 0 |
| EV / EBITDA | -0.49 |
| EV / EBIT | -0.54 |
| EV / FCF | -0.53 |
Financial Position
The company has a current ratio of 4.81, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.81 |
| Quick Ratio | 4.81 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | -0.24 |
| Interest Coverage | -53.66 |
Financial Efficiency
Return on Equity is -77.03% and Return on Invested Capital is -66.98%.
| Return on Equity | -77.03% |
| Return on Assets | -51.07% |
| Return on Invested Capital | -66.98% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-926.54K |
| Employee Count | 68 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 240K |
| Effective Tax Rate | -0.38% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is -0.4, so Decibel Therapeutics's price volatility has been lower than the market average.
| Beta | -0.4 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 4.61 |
| 200-Day Moving Average | 3.72 |
| Relative Strength Index (RSI) | 51.68 |
| Average Volume (20 Days) | 214.74K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -63.96M |
| Net Income | -63.01M |
| EBITDA | -62.49M |
| EBIT | -61.57M |
| Earnings Per Share (EPS) | -2.52 |
Balance Sheet
The company has 34.61M in cash and 14.05M in debt, giving a net cash position of 20.55M.
| Cash & Cash Equivalents | 34.61M |
| Total Debt | 14.05M |
| Net Cash | 20.55M |
| Retained Earnings | -277.52M |
| Total Assets | 94.39M |
| Working Capital | 53.87M |
Cash Flow
In the last 12 months, operating cash flow was -56.9M and capital expenditures -463K, giving a free cash flow of -57.36M.
| Operating Cash Flow | -56.9M |
| Capital Expenditures | -463K |
| Free Cash Flow | -57.36M |
| FCF Per Share | -2.3 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DBTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -123.13% |
| FCF Yield | -112.1% |
Analyst Forecast
Currently there are no analyst rating for DBTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -4.4 |
| Piotroski F-Score | 2 |